A recent study found that participants who practice mindfulness reported significantly less severe symptoms of anxiety, ...

Researchers estimate the number of people globally living with chronic obstructive pulmonary disease (COPD) will hit 600 million by 2050. There are certain risk factors for COPD, including obesity ...

Share on Pinterest GLP-1 and SGLT-2 drugs may be the best treatments for people with type 2 diabetes and COPD. Image credit: Visual Vic/Getty Images. Researchers estimate the number of people ...

For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 ...

Chronic Obstructive Pulmonary disease (COPD) has been around for almost 205 years and is one of the most prevalent non-infectious diseases in our country. It is the 2nd leading cause of death and ...

GSK plc has announced that the China National Medical Products Administration has accepted for review the new drug ...

China NMPA accepts for review GSK’s Nucala NDA to treat patients with chronic obstructive pulmonary disease: London, UK Friday, February 21, 2025, 09:00 Hrs [IST] GSK plc announ ...

Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This ...

Lower risk for COPD exacerbations seen with SGLT-2 inhibitors ... treated with GLP-1 RAs versus DPP-4is (9.26 vs 11.4 per 100 person-years [hazard ratio, 0.81] and 9.89 vs 11.49 per 100 person ...